Jun 2026 (Q2 FY26) — Aug 6, 2026
Ocugen Q2 FY26 — FDA Clearances, RMAP Designation, and Extended Cash Runway
Read the full callOcugen (OCGN) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Ocugen earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1.5 | +8.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -1105.1 | −100.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -24.9 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$0.79 +1.28% · +$0.01
Performance −50.6% 1Y
1Y: $1.6 on 17 Oct 2025 → $0.79. High $2.48 (13 Mar 2026), low $0.78 (16 Oct 2026).
- Previous close
- $0.78
- 52-week range
- $0.78 – $2.48
- One year
- −51.23%
Overview
- Symbol
- OCGN
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Ocugen earnings calls (OCGN)
Financials
What the filings say
Net profit, year on year: −69% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 1 | 1 | 1 | 2 | — | 2 | 1 |
| Operating profit | -13 | -14 | -15 | -14 | -18 | -17 | -18 | -16 |
| Operating margin | −1166.5% | −1811.5% | −979.1% | −1004.7% | −1006.0% | — | −1163.7% | −1105.1% |
| Other income | 0 | -0 | -1 | -1 | -2 | -1 | -1 | -8 |
| Interest | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 4 |
| Net profit | -13 | -14 | -15 | -15 | -20 | -18 | -19 | -25 |
| EPS ($ per share) | — | — | -0.05 | -0.05 | — | — | -0.06 | -0.07 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 1 | 2 | 2 | 2 | 3 | 3 | 3 |
| Reserves | 31 | -51 | -73 | -132 | -223 | -286 | -340 | -408 |
| Total liabilities | 15 | 6 | 6 | 10 | 35 | 24 | 53 | 56 |
| Fixed assets | 0 | 0 | 1 | 1 | 6 | 17 | 17 | 14 |
| Total assets | 2 | 17 | 27 | 106 | 109 | 65 | 82 | 44 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -12 | -17 | -15 | -48 | -60 | -62 | -42 | -57 |
| Cash from investing | -0 | -2 | -0 | -2 | -17 | 3 | -3 | -0 |
| Cash from financing | 7 | 25 | 32 | 121 | 59 | 21 | 65 | 17 |
| Net cash flow | -5 | 6 | 17 | 71 | -18 | -38 | 19 | -40 |
| Capital expenditure | -0 | -0 | -0 | -1 | -4 | -10 | -3 | -0 |
| Free cash flow | -12 | -17 | -15 | -49 | -65 | -73 | -46 | -57 |
Insider filings
10 filings between Jan 2, 2026 and Oct 9, 2026.
Open market
decisions to buy or sellPurchases
$25.8K
1 purchase by 1 insider
Sales
$1.09M
4 sales by 1 insider
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 2
- Award — granted as compensation
- 3
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Musunuri Shankar | — | $1.09M | Oct 9, 2026 |
| Johnson-Greene Treerita Essalima | $25.8K | — | Jun 15, 2026 |
Latest filings (15)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 9, 2026 | Musunuri Shankar Chief Executive Officer | Sale 10b5-1 plan | 57,264 | $54.4K |
| Oct 9, 2026 | Musunuri Shankar Chief Executive Officer | Sale 10b5-1 plan | 468,727 | $445.3K |
| Sep 9, 2026 | Musunuri Shankar Chief Executive Officer | Sale 10b5-1 plan | 468,727 | $525.0K |
| Sep 9, 2026 | Musunuri Shankar Chief Executive Officer | Sale 10b5-1 plan | 57,264 | $64.1K |
| Jun 15, 2026 | Johnson-Greene Treerita Essalima Chief Financial Officer | Purchase | 21,000 | $25.8K |
| Apr 1, 2026 | Zhang Junge Director | Option exercise | 66,929 | $95.0K |
| Apr 1, 2026 | Zhang Junge Director | Option exercise | 112,205 | $51.6K |
| Apr 1, 2026 | Zhang Junge Director | Option exercise | 15,000 | $7.7K |
| Jan 2, 2026 | Ramachandran Ramesh Chief Accounting Officer | Award | 207,300 | $0 |
| Jan 2, 2026 | Musunuri Shankar Chief Executive Officer | Award | 3,123,201 | $0 |
| Jan 3, 2025 | Upadhyay Arun See Remarks | Tax withheld | 41,633 | $37.2K |
| Jan 3, 2025 | Musunuri Shankar Chief Executive Officer | Tax withheld | 177,146 | $158.5K |
| Nov 26, 2024 | Fernandes Prabhavathi Director | Purchase | 10,000 | $9.1K |
| Nov 22, 2024 | Castillo Kirsten Director | Purchase | 25,000 | $22.8K |
| Sep 16, 2024 | Upadhyay Arun See Remarks | Tax withheld | 842 | $985 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Ocugen, Inc.
Free account. Everything above stays public.
Write why you follow Ocugen, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading